Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.
In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website.
October 4, 2012
Gothenburg
Xvivo Perfusion AB (publ)
Magnus Nilsson
CEO